1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Boston Scientific Becomes Third US TAVR Competitor With Lotus Edge Approval

 
• By Reed Miller

The US FDA approved Boston Scientific's Lotus Edge transcatheter aortic valve for patients who would be at high risk with surgical valve replacement. Unlike competing TAVR systems from Medtronic and Edwards, Lotus Edge can be repositioned or recaptured after it has been deployed.

New competition business concept with a chess pawn punching and destroying competitors as two king pieces with hidden red boxing gloves as a metaphor for innovative corporate attack strategy. - Illustration
• Source: shutterstock.com

Boston Scientific Corp. immediately began a limited US launch of its Lotus Edge mechanically expanded transcatheter aortic valve replacement (TAVR) system after the US Food & Drug Administration approved it on 23 April.

Lotus Edge will compete with Edwards Lifesciences Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation